Francis Crick researchers reveal pathways linking intestinal inflammation and colitis
Affecting over 500,000 people in the UK, IBD comprises Crohn’s disease and ulcerative colitis
Read Moreby Jen Brogan | Apr 15, 2024 | News | 0
Affecting over 500,000 people in the UK, IBD comprises Crohn’s disease and ulcerative colitis
Read Moreby John Pinching | Jul 28, 2023 | News | 0
Mage Biologics aims to progress a novel, orally administered monoclonal antibody
Read Moreby Lucy Parsons | Aug 11, 2021 | News | 0
The clinical development programme is now known as TAK-524
Read Moreby Lucy Parsons | Jul 23, 2021 | News | 0
Microbiome-based therapeutic failed to improve clinical remission rates among mild-to-moderate ulcerative colitis patients
Read Moreby Lucy Parsons | Jul 12, 2021 | News | 0
Data also suggested filgotinib 200mg reduced and eliminated corticosteroid use compared to placebo
Read Moreby Lucy Parsons | Jul 1, 2021 | News | 0
JAK inhibitor hit primary endpoint of improved clinical remission at 52 weeks in maintenance study
Read Moreby Lucy Parsons | May 26, 2021 | News | 0
Once-daily oral treatment was well-tolerated and demonstrated a good safety profile in Phase IIb study
Read Moreby Lucy Parsons | Mar 17, 2021 | News | 0
Patients treated with monoclonal antibody achieved clinical remission at week 12
Read Moreby Lucy Parsons | Nov 3, 2020 | News | 0
Gilead and Galapagos’ application for oral JAK1 inhibitor validated by agency
Read Moreby Lucy Parsons | Oct 12, 2020 | News | 0
Oral S1P receptor modulator hit both primary endpoints in a phase III trial
Read Moreby Lucy Parsons | Aug 10, 2020 | News | 0
Phase III study of drug in Crohn’s disease is ongoing
Read Moreby Selina McKee | Jun 17, 2020 | News | 0
The drug will be funded on the NHS to treat ulcerative colitis under certain conditions
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479